Hopkins Andrew L, Groom Colin R
Molecular Informatics, Structure and Design Department, Pfizer Global Research & Development, Sandwich, Kent, CT13 9NJ, UK.
Nat Rev Drug Discov. 2002 Sep;1(9):727-30. doi: 10.1038/nrd892.
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
评估代表治疗干预机会的分子靶点数量对于制药行业后基因组研究策略的发展至关重要。既然我们已经知道了人类基因组的大小,那么思考一下这个机会所代表的分子靶点数量就很有意思了。我们从这样一个立场出发,即我们了解一种优质药物所需的特性,因此必须能够理解是什么造就了一个优质的药物靶点。